Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study

Berry, 1984, The development of human benign prostatic hyperplasia with age, J Urol, 132, 474, 10.1016/S0022-5347(17)49698-4 Jacobsen, 1995, New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States, Arch Intern Med, 155, 477, 10.1001/archinte.155.5.477 McConnell, 1994, Benign prostatic hyperplasia: Diagnosis and treatment White, 1985, The results of double castration on hypertrophy of the prostate, Ann Surg, 25, 1 Peters, 1987, The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist on benign prostatic hyperplasia, NEJM, 317, 599, 10.1056/NEJM198709033171004 Schröder, 1987, Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: A report of 6 cases, Eur Urol, 12, 318, 10.1159/000472646 Gormley, 1992, The effect of finasteride in men with benign prostatic hyperplasia, NEJM, 327, 1187, 10.1056/NEJM199210223271701 1993, Finasteride (MK-906) in the treatment of benign prostatic hyperplasia, Prostate, 22, 291, 10.1002/pros.2990220403 Stoner, 1994, Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia, Urology, 43, 284, 10.1016/0090-4295(94)90068-X Lepor, 1995, Long-term results of medical therapies for benign prostatic hyperplasia, Curr Opin Urol, 5, 18, 10.1097/00042307-199501000-00005 Moore, 1993, Proscar®: Five-year experience, Eur Urol, 28, 304, 10.1159/000475071 Boyle, 1996, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials, J Urol, 48, 398, 10.1016/S0090-4295(96)00353-6 Sorva, 1988, Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males, Atherosclerosis, 69, 191, 10.1016/0021-9150(88)90014-7 Marin, 1995, Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: Effects of androgens, J Clin Endocrinol Metab, 80, 239, 10.1210/jc.80.1.239 Barry, 1992, The American Urological Association Symptom Index for benign prostatic hyperplasia, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5 Barry, 1995, Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association, Med Care, 33, AS145 Epstein, 1992, Validation of a new quality of life questionnaire for benign prostatic hyperplasia, J Clin Epidemiol, 45, 1431, 10.1016/0895-4356(92)90205-2 Steiner, 1981, Standardization of micromethods for plasma cholesterol, triglyceride, and HDL-cholesterol with the lipid clinics' methodology, J Clin Chem, 19, 850 Andersen, 1995, Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study, Urology, 46, 631, 10.1016/S0090-4295(99)80291-X Girman, 1996, Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia, Prostate, 29, 83, 10.1002/(SICI)1097-0045(199608)29:2<83::AID-PROS3>3.0.CO;2-I Byrnes, 1995, Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: A community based study, Clin Ther, 17, 956, 10.1016/0149-2918(95)80073-5 Guess, 1993, The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia, Prostate, 22, 31, 10.1002/pros.2990220105 Guess, 1993, Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American Phase III Clinical Trial, Urol Clin North Am, 20, 627 Plawker, 1996, Primary care practitioners: An analysis of their perceptions of voiding dysfunction and prostate cancer, J Urol, 155, 601, 10.1016/S0022-5347(01)66462-0